In recent years interest in cancer metabolism has risen. A relevant role of the pentose phosphate pathway (PPP) is recognized in cancer metabolic reprogramming, involving both the cytosolic glucose-6-phosphate dehydrogenase (G6PD) and especially the less characterized endoplasmic reticulum (ER) hexose-6-phosphate dehydrogenase (H6PD). In breast and lung cancer cells, H6PD gene silencing decreased PPP intermediates content, similarly to G6PD silencing. G6PD or H6PD gene silencing impaired at a similar extent NADPH content, proliferating activity, and oxidative status of the cancer cell1. Cancer cells may direct glucose flux to the PPP to produce ribose-5-phosphate for nucleic acid biosynthesis and of NADPH for regulation of the cell redox state. Cancer cells metabolic disturbances can trigger an ER stress, that if not relieved by activating the unfolded protein response (UPR), can activate PERK/ATF6/IRE1α-mediated apoptosis pathways. The substrates for H6PD are many hexoses also non-phosphorylated. It was supposed that galactose could become the substrate of H6PD, generating xylulose2. Notably, a xylulokinase (EC 2.7.1.17) exists and its product, xylulose-5-phosphate, determines the respective flux rates of the oxidative and non-oxidative PPP. The latter involves transketolase and transaldolase enzymes for the interconversion of sugar phosphate intermediates. It was shown that transketolase (TKT) is required for cancer growth. A transketolase-like 1 (TKTL1) enzyme was found3 in aggressive cancers, suggestive of rapid glucose utilization. TKTL1 would act on xylulose-5-phosphate to generate cytosolic lipogenesis precursors. The study of the reticular PPP and of the role of H6PD in ER redox balance might help our comprehension of the cancer cell biology. Moreover, targeting H6PD to disturb the ER redox homeostasis of cancer cells by either genetic knockdown or pharmacologic intervention provides a promising approach for cancer therapy.
Endoplasmic reticulum pentose phosphate pathway in the cancer cell redox state and fate.
Isabella Panfoli
2023-01-01
Abstract
In recent years interest in cancer metabolism has risen. A relevant role of the pentose phosphate pathway (PPP) is recognized in cancer metabolic reprogramming, involving both the cytosolic glucose-6-phosphate dehydrogenase (G6PD) and especially the less characterized endoplasmic reticulum (ER) hexose-6-phosphate dehydrogenase (H6PD). In breast and lung cancer cells, H6PD gene silencing decreased PPP intermediates content, similarly to G6PD silencing. G6PD or H6PD gene silencing impaired at a similar extent NADPH content, proliferating activity, and oxidative status of the cancer cell1. Cancer cells may direct glucose flux to the PPP to produce ribose-5-phosphate for nucleic acid biosynthesis and of NADPH for regulation of the cell redox state. Cancer cells metabolic disturbances can trigger an ER stress, that if not relieved by activating the unfolded protein response (UPR), can activate PERK/ATF6/IRE1α-mediated apoptosis pathways. The substrates for H6PD are many hexoses also non-phosphorylated. It was supposed that galactose could become the substrate of H6PD, generating xylulose2. Notably, a xylulokinase (EC 2.7.1.17) exists and its product, xylulose-5-phosphate, determines the respective flux rates of the oxidative and non-oxidative PPP. The latter involves transketolase and transaldolase enzymes for the interconversion of sugar phosphate intermediates. It was shown that transketolase (TKT) is required for cancer growth. A transketolase-like 1 (TKTL1) enzyme was found3 in aggressive cancers, suggestive of rapid glucose utilization. TKTL1 would act on xylulose-5-phosphate to generate cytosolic lipogenesis precursors. The study of the reticular PPP and of the role of H6PD in ER redox balance might help our comprehension of the cancer cell biology. Moreover, targeting H6PD to disturb the ER redox homeostasis of cancer cells by either genetic knockdown or pharmacologic intervention provides a promising approach for cancer therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



